Published in Oncotarget on March 20, 2015
Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget (2016) 0.81
Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. J Gastrointest Oncol (2016) 0.77
Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer. Oncotarget (2016) 0.77
Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death Dis (2017) 0.77
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget (2016) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Colorectal cancer. Lancet (2010) 8.36
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res (2003) 1.91
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol (2007) 1.63
Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev (2008) 1.56
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol (2011) 1.52
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer (2004) 1.40
Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol (2010) 1.13
Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur J Cancer (2003) 1.02
Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin (2011) 0.92
Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol (2009) 0.90
Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils. Ann Surg Oncol (2010) 0.86
Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol (2011) 0.85
Patterns of gene expression that characterize the colonic mucosa in patients at genetic risk for colonic cancer. Proc Natl Acad Sci U S A (1991) 0.85
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol (2012) 0.84
Visinin-like protein-1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients. Int J Cancer (2011) 0.83
SEOM clinical guidelines for the treatment of advanced colorectal cancer 2013. Clin Transl Oncol (2013) 0.81
Involvement of visinin-like protein-1 (VSNL-1) in regulating proliferative and invasive properties of neuroblastoma. Carcinogenesis (2007) 0.80